I earned a bachelor’s degree in Applied Chemistry from the Nova School of Science and Technology and a master’s degree in Pharmaceutical and Therapeutical Chemistry from the Faculty of Pharmacy of the University of Lisbon. During my master’s thesis, I commenced my professional career with an internship at Hovione Farmaciência, where I immersed myself in Current Good Manufacturing Practice (CGMP) Regulations and international standards. Transitioning to Recipharm in 2019, I started as an Analytical Chemist, and in 2022, I advanced to Senior Analytical Chemist. During this tenure, I conducted analyses of final products using various analytical techniques, significantly contributing to the validation of numerous product methods. Since October 2022, I have been an integral part of the esteemed Glycoimmunology group at the UCIBIO research unit, renowned for groundbreaking research on the role of glycans in immune responses, particularly in cancer immunotherapy (Glycoimmunology Group). The group collaborates extensively with clinical teams, biotech and pharma companies, and patient associations on several multidisciplinary national and international Glycosciences projects. I notably contributed to the DCMatters project, focused on studying the use of vaccines in advanced tumors. As a Master’s researcher, I developed an in-silico approach comprising QSAR modeling, molecular docking, and virtual screening to discover lead-like small-molecule checkpoint PD-1/PD-L1 inhibitors, fostering synergy among Stemmatters, IPO Porto, CINTESIS, and our group. My research in this project led to the publication of the article "Advancements in drug discovery: integrating CADD tools and drug repurposing for PD-1/PD-L1 axis inhibition", which was published in January 2025. I was also involved in the ProDGNE project, a 3-year transnational research endeavor aimed at developing a therapeutic compound for GNE Myopathy (GNEM), funded under the European Joint Programme on Rare Diseases. In this project, I contributed my knowledge in pharmaceutical regulations and cheminformatics, while expanding my expertise through new computational approaches and techniques. The project successfully concluded in July 2024. In 2024, I was awarded a PhD grant and have now commenced my PhD in Sustainable Chemistry. My research focuses on "Computational approaches to target glyco-immune checkpoints in CAR T-cell: opportunities for novel small-molecule therapeutics", combining my cheminformatics expertise with the emerging field of glycoimmunology in cancer therapy. Beyond my research, I contributed to NOVA FCT initiatives, promoting the Navmol project for molecule representation by blind users, culminating in my participation as an investigator at the European Researchers' Night 2023. Additionally, I have been involved in developing a Moodle glycoimmunology course in collaboration with the Pedagogical Innovation Office from NOVA FCT, as well as managing social media for our Glycoimmunology group. I have authored the article "Computational Approaches Drive Developments in Immune-Oncology Therapies for PD-1/PD-L1 Immune Checkpoint Inhibitors", published in IJMS (Impact Factor: 5.6, Q1 ranking), which has already received nine citations in two years. Additionally, I co-authored "Generation of monocyte-derived dendritic cells with differing sialylated phenotypes", published in JoVE, renowned for its peer-reviewed scientific video protocols, with associated videos accumulating nearly 1,900 views. Moreover, I have two articles in submission—one from my work at Hovione and another related to the ProDGNE project. I presented my DCMatters research at the 23rd Tetrahedron Symposium in Gothenburg, Sweden, and at the NOVA Health Chronic Disease and Infection conference in Lisbon, Portugal, where I was awarded Best Poster. Additionally, I attended the workshop “Together we are the strongest: breaking the limit of protein-carbohydrate interactions” in Siena, Italy,